Levo Phencynonate Hydrochloride for the Prevention of Seasickness

Status Completed

Clinical Trial Summary

A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.

Clinical Trial Description

The trial is composed by 3 parts: 1) On-boat screening period for seasickness and safety tests will be evaluated in minus one day. 2) 4 weeks of washout period to eliminate the impact of voyage experience. 3) On-boat drug testing period. The subjects will be administered the drug before voyage. The seasickness symptoms will be evaluated during voyage. The safety test will be conducted before and after one day of on-boat testing. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Motion Sickness

Clinical Trial Details

NCT number	NCT02241629
Study type	Interventional
Source	Sihuan Pharmaceutical Holdings Group Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2014
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Recruiting	`NCT06128707` - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed	`NCT05611814` - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms	N/A
Recruiting	`NCT06106256` - Three-Axis Wearable Adaptive Vestibular Stimulator	N/A
Completed	`NCT02839135` - A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.	Phase 1
Completed	`NCT04420949` - Sensory Training for Visual Motion Sickness	N/A
Completed	`NCT04184115` - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness	Phase 3
Completed	`NCT03988530` - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects	Phase 3
Terminated	`NCT04219982` - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness	Phase 2/Phase 3
Terminated	`NCT02155309` - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray	Phase 2/Phase 3
Completed	`NCT04947423` - Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion	Phase 3
Recruiting	`NCT05903924` - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3
Recruiting	`NCT04999449` - Nebulizer Delivery of Intranasal Scopolamine	Phase 1
Recruiting	`NCT05886660` - Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance	Phase 2
Completed	`NCT03755596` - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness	Phase 4
Recruiting	`NCT05628220` - Motion Sickness Desensitization Using VR	N/A
Recruiting	`NCT06138613` - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3
Completed	`NCT04327661` - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Phase 3
Completed	`NCT06232785` - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients	Phase 4
Completed	`NCT06056622` - Motion Sickness Rehabilitation for Virtual Reality	N/A